Patents by Inventor Mari Adachi
Mari Adachi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12122815Abstract: The present disclosure provides GIP receptor agonist peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of diabetes, obesity, emesis, or a symptom or condition associated with diabetes, obesity, or emesis. Specifically, a GIP receptor agonist peptide containing a sequence represented by the formula (I) or a salt thereof, and a medicament comprising the same are provided. Formula I: P1-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-P2 (SEQ ID NO: 4), or a salt thereof, wherein each symbol is as defined herein, with the proviso that the GIP receptor agonist peptide does not have an amino acid sequence as provided in SEQ ID NOs: 328-893.Type: GrantFiled: September 24, 2019Date of Patent: October 22, 2024Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Hiroshi Imoto, Mari Adachi, Yoko Kanematsu, Taiji Asami, Ayumu Niida, Naoki Nishizawa, Derek Cecil Cole, Mack Flinspach, Nick Scorah, Abhijit Suresh Bhat
-
Publication number: 20220135638Abstract: The present disclosure provides GIP receptor agonist peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of diabetes, obesity, emesis, or a symptom or condition associated with diabetes, obesity, or emesis. Specifically, a GIP receptor agonist peptide containing a sequence represented by the formula (I) or a salt thereof, and a medicament comprising the same are provided. Formula I: P1-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A341-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-P2 (SEQ ID NO: 4), or a salt thereof, wherein each symbol is as defined herein, with the proviso that the GIP receptor agonist peptide does not have an amino acid sequence as provided in SEQ ID NOs: 4-569 disclosed in PCT/JP2018/013540.Type: ApplicationFiled: September 24, 2019Publication date: May 5, 2022Inventors: Hiroshi IMOTO, Mari ADACHI, Yoko KANEMATSU, Taiji ASAMI, Ayumu NIIDA, Naoki NISHIZAWA, Derek Cecil COLE, Mack FLINSPACH, Nick SCORAH, Abhijit Suresh BHAT
-
Patent number: 11174301Abstract: The present invention provides a novel peptide compound having an activating action on GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. P1-Tyr-A2-Glu-Gly-Thr-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-P2?? (I) wherein each symbol is as defined herein.Type: GrantFiled: August 29, 2019Date of Patent: November 16, 2021Assignee: Takeda Pharmaceutical Company LimitedInventors: Taiji Asami, Naoki Nishizawa, Ayumu Niida, Yoko Kanematsu, Mari Adachi, Shiro Takekawa, Tomoko Morimoto
-
Publication number: 20200140505Abstract: The present invention provides a novel peptide compound having an activating action on GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. P1-Tyr-A2-Glu-Gly-Thr-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-P2?? (I) wherein each symbol is as defined herein.Type: ApplicationFiled: August 29, 2019Publication date: May 7, 2020Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMTEDInventors: TAIJI ASAMI, NAOKI NISHIZAWA, AYUMU NIIDA, YOKO KANEMATSU, MARI ADACHI, SHIRO TAKEKAWA, TOMOKO MORIMOTO
-
Patent number: 10435445Abstract: The present invention provides a novel peptide compound having an activating action on GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. (I) P1-Tyr-A2-Glu-Gly-Thr-A6-A7-A8-A9-A10-A11-A12-A13- A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25- A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37- A38-A39-A40-P2 wherein each symbol is as defined herein.Type: GrantFiled: March 30, 2018Date of Patent: October 8, 2019Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Taiji Asami, Naoki Nishizawa, Ayumu Niida, Yoko Kanematsu, Mari Adachi, Shiro Takekawa, Tomoko Morimoto
-
Publication number: 20180298070Abstract: The present invention provides a novel peptide compound having an activating action on GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. P1-Tyr-A2-Glu-Gly-Thr-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-P2 ??(I) wherein each symbol is as defined herein.Type: ApplicationFiled: March 30, 2018Publication date: October 18, 2018Applicant: Takeda Pharmaceutical Company LimitedInventors: Taiji Asami, Naoki Nishizawa, Ayumu Niida, Yoko Kanematsu, Mari Adachi, Shiro Takekawa, Tomoko Morimoto
-
Patent number: 7420070Abstract: A process for preparing optically active 2,3-dihydrobenzofuran compounds which comprises subjecting a 2,3-dihydrobenzofuran compound represented by the general formula or a salt thereof to optical resolution with an optically active acid compound: [wherein R1 and R2 are each hydrogen or an optionally substituted hydrocarbon group; R3 is an optionally substituted aromatic group; and C is a benzene ring which may further have a substituent in addition to the amino group]. The process enables industrially advantageous production of intermediates for the synthesis of optically active 2,3-dihydrobenzofuran compounds useful as preventive and/or therapeutic drugs for neurodegenerative diseases and so on.Type: GrantFiled: February 9, 2005Date of Patent: September 2, 2008Assignee: Takoda Pharmaceutical Company LimitedInventors: Isao Aoki, Mari Adachi, Hiroyuki Tawada, Makoto Yamashita, Misayo Sera
-
Publication number: 20050171184Abstract: A process for preparing optically active 2,3-dihydrobenzofuran compounds which comprises subjecting a 2,3-dihydrobenzofuran compound represented by the general formula or a salt thereof to optical resolution with an optically active acid compound: [wherein R1 and R2 are each hydrogen or an optionally substituted hydrocarbon group; R3 is an optionally substituted aromatic group; and C is a benzene ring which may further have a substituent in addition to the amino group]. The process enables industrially advantageous production of intermediates for the synthesis of optically active 2,3-dihydrobenzofuran compounds useful as preventive and/or therapeutic drugs for neurodegenerative diseases and so on.Type: ApplicationFiled: February 9, 2005Publication date: August 4, 2005Inventors: Isao Aoki, Mari Adachi, Hiroyuki Tawada, Makoto Yamashita, Misayo Sera
-
Publication number: 20050107606Abstract: A process for preparing an optically active sulfoxide derivative (I) having CCR5 antagonism without causing side reactions such as racemization and Pummerer rearrangement, which comprises reacting a compound (II) with a compound (III) as shown by the following scheme: wherein R1 represents hydrogen, an aliphatic hydrocarbon group or an aromatic group; R2 represents halogeno, alkyl, hydroxyl, amino, an aromatic group, etc.; R3 represents a 5- or 6-membered ring; R4 represents hydrogen, alkyl, alkoxy or halogeno; R5 represents hydrogen, a hydrocarbon group, a heterocyclic group, acyl, etc.; ring A represents an optionally substituted benzene ring; X represents a bond or divalent group comprising a linear part constituted of 1 to 4 atoms; m represents an integer of 1 to 5; n represents an integer of 0 to 3; p represents an integer of 0 to 2; and *1 represents an asymmetric center.Type: ApplicationFiled: March 11, 2003Publication date: May 19, 2005Inventors: Hiroyuki Tawada, Tomomi Ikemoto, Atsuko Nishiguchi, Tatsuya Ito, Mari Adachi
-
Patent number: 6878831Abstract: A process for preparing optically active 2,3-dihydrobenzofuran compounds which comprises subjecting a 2,3-dihydrobenzofuran compound represented by the general formula or a salt thereof to optical resolution with an optically active acid compound: [wherein R1 and R2 are each hydrogen or an optionally substituted hydrocarbon group; R3 is an optionally substituted aromatic group; and C is a benzene ring which may further have a substituent in addition to the amino group]. The process enables industrially advantageous production of intermediates for the synthesis of optically active 2,3-dihydrobenzofuran compounds useful as preventive and/or therapeutic drugs for neurodegenerative diseases and so on.Type: GrantFiled: December 27, 2001Date of Patent: April 12, 2005Assignee: Takeda Chemical Industries, Ltd.Inventors: Isao Aoki, Mari Adachi, Hiroyuki Tawada, Makoto Yamashita, Misayo Sera
-
Patent number: 6800778Abstract: The present invention provides a method of producing an optically active form of a compound represented by the formula (I) having a steroid C17,20-lyase inhibitory activity and is useful as an agent for the prophylaxis or treatment of prostatism, tumor such as breast cancer, and the like or a salt thereof, which method includes reacting a mixture of optically active compounds of a naphthalene derivative represented by the formula: wherein R is a nitrogen-containing heterocyclic group, R1 is a hydrogen atom, a hydrocarbon group or an aromatic heteromonocyclic group, R2 is a hydrogen atom or a lower alkyl group, * shows the position of an asymmetric carbon, R3, R4, R5, R6, R7, R8 and R9 are each independently a hydrogen atom, a hydrocarbon group, a hydroxy group, a thiol group, an amino group, a carbamoyl group, an acyl group or a halogen atom, and R7 is bonded with R6 or R8 to form, together with a carbon atom on a naphthalene ring, a 5 or 6-membered ring containing an oxygen atom, with an opType: GrantFiled: April 22, 2002Date of Patent: October 5, 2004Assignee: Takeda Chemical Industries, Ltd.Inventors: Isao Aoki, Mari Adachi, Mitsuru Kawada, Toru Yamano, Naohiro Taya
-
Publication number: 20040077712Abstract: A process for preparing optically active 2,3-dihydrobenzofuran compounds which comprises subjecting a 2,3-dihydrobenzofuran compound represented by the general formula or a salt thereof to optical resolution with an optically active acid compound: 1Type: ApplicationFiled: June 24, 2003Publication date: April 22, 2004Inventors: Isao Aoki, Mari Adachi, Hiroyuki Tawada, Makoto Yamashita, Misayo Sera
-
Publication number: 20040033935Abstract: The present invention provides a compound having a steroid C17,20-lyase-inhibitory activity and useful for the therapy and prophylaxis of tumor such as prostatism, breast cancer and the like, and a method for efficiently separating an optically active compound of this compound from a mixture of optical isomers thereof, a compound of the formula: 1Type: ApplicationFiled: May 16, 2003Publication date: February 19, 2004Inventors: Akihiro Tasaka, Takenori Hitaka, Nobuyuki Matsunaga, Masami Kusaka, Mari Adachi, Isao Oaki, Akio Ojida